Loading stock data…
$0.78-0.02 (-3.12%)
Cognition Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina.
Cognition Therapeutics, Inc. in the Healthcare sector is trading at $0.79 with a market capitalization of $83M. Wall Street consensus targets $3.33 (3 analysts), implying a +323.4% move over the next 12 months. The stock is currently near its 52-week low of $0.55, remaining 29.1% below its 200-day moving average. On fundamentals, Piotroski 3/9 flags weak fundamentals, Altman Z in the distress zone. Risk note: RSI 23 is oversold, raising the odds of a near-term bounce; MACD remains below its signal line. The Whystock Score of 55/100 suggests a balanced risk-reward profile.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$4.22M↑ | -$4.84M↓ | -$3.67M↑ | -$5.16M↑ | -$6.87M |
| Net Income | -$3.93M↑ | -$4.57M↓ | -$3.34M↑ | -$4.93M↑ | -$6.73M |
Cognition Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its ...